Is VTVT or MIRA more profitable?

vTv Therapeutics' return on equity of -6.27% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% MIRA Pharmaceuticals N/A -106.95% -104.18%

Is MIRA or UNCY more profitable?

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Unicycive Therapeutics N/A -91.50% -61.47%

Which has higher earnings & valuation, MIRA or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is MIRA or VANI more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Vivani Medical N/A -191.05% -70.91%

Which has better valuation & earnings, AARD or MIRA?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is AARD or MIRA more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% MIRA Pharmaceuticals N/A -106.95% -104.18%

MIRA Pharmaceuticals (MIRA) Competitors

$0.68 +0.01 (+1.29%)

As of 02:30 PM Eastern

Compare

MIRA vs. LENZ, VTVT, UNCY, VANI, and AARD

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MIRA Pharmaceuticals's main competitors and comparable companies include LENZ Therapeutics (LENZ), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), Vivani Medical (VANI), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MIRA Pharmaceuticals compare to LENZ Therapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

MIRA Pharmaceuticals has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
LENZ Therapeutics	$19.09M	5.60	-$82.13M	-$4.09	N/A

In the previous week, LENZ Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for LENZ Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat LENZ Therapeutics' score of 0.95 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
LENZ Therapeutics	Positive

MIRA Pharmaceuticals has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

MIRA Pharmaceuticals presently has a consensus target price of $3.50, suggesting a potential upside of 425.21%. LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 747.06%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LENZ Therapeutics beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, vTv Therapeutics had 8 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 9 mentions for vTv Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat vTv Therapeutics' score of 0.27 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
MIRA Pharmaceuticals	Very Positive

vTv Therapeutics' return on equity of -6.27% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 97.78%. MIRA Pharmaceuticals has a consensus price target of $3.50, suggesting a potential upside of 425.21%. Given MIRA Pharmaceuticals' higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MIRA Pharmaceuticals has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	109.05	-$26.97M	-$1.06	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

vTv Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Summary

vTv Therapeutics beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Unicycive Therapeutics had 10 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat Unicycive Therapeutics' score of 0.06 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
Unicycive Therapeutics	Neutral

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

MIRA Pharmaceuticals has higher earnings, but lower revenue than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Unicycive Therapeutics	$680K	152.77	-$26.56M	-$1.75	N/A

MIRA Pharmaceuticals presently has a consensus target price of $3.50, indicating a potential upside of 425.21%. Unicycive Therapeutics has a consensus target price of $18.25, indicating a potential upside of 389.28%. Given MIRA Pharmaceuticals' higher possible upside, equities research analysts plainly believe MIRA Pharmaceuticals is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market.

Summary

Unicycive Therapeutics beats MIRA Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Vivani Medical?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

In the previous week, Vivani Medical had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Vivani Medical and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat Vivani Medical's score of 1.25 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
Vivani Medical	Positive

MIRA Pharmaceuticals' return on equity of -106.95% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Vivani Medical	N/A	-191.05%	-70.91%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 53.3% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MIRA Pharmaceuticals presently has a consensus target price of $3.50, suggesting a potential upside of 425.21%. Vivani Medical has a consensus target price of $3.75, suggesting a potential upside of 217.80%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Vivani Medical is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

MIRA Pharmaceuticals beats Vivani Medical on 6 of the 11 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Aardvark Therapeutics' return on equity of -71.54% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Aardvark Therapeutics currently has a consensus target price of $13.13, suggesting a potential upside of 224.88%. MIRA Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 425.21%. Given MIRA Pharmaceuticals' higher probable upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aardvark Therapeutics has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 25 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat Aardvark Therapeutics' score of 0.14 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
MIRA Pharmaceuticals	Very Positive

Summary

Aardvark Therapeutics beats MIRA Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.03M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.54	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	2.68	9.21	10.55	5.95
Net Income	-$10.44M	$2.84B	$3.50B	$380.75M
7 Day Performance	-5.63%	-4.00%	-3.92%	-3.96%
1 Month Performance	-10.98%	-8.07%	-8.30%	-6.81%
1 Year Performance	-48.85%	-5.86%	2.35%	-4.58%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	3.0123 of 5 stars	$0.68 +1.3%	$3.50 +418.5%	-48.1%	$28.03M	N/A	N/A	2	Positive News
LENZ LENZ Therapeutics	2.7836 of 5 stars	$3.79 +5.6%	$28.80 +659.9%	-91.2%	$119.08M	$19.09M	N/A	152
VTVT vTv Therapeutics	3.1466 of 5 stars	$30.03 -1.0%	$55.83 +85.9%	+29.4%	$118.29M	$36.84M	N/A	26	Analyst Forecast
UNCY Unicycive Therapeutics	2.7205 of 5 stars	$4.23 +1.0%	$18.25 +331.4%	-16.9%	$117.81M	$680K	N/A	22	Trending News
VANI Vivani Medical	2.9951 of 5 stars	$1.24 +1.6%	$3.75 +202.4%	-12.9%	$111.85M	N/A	N/A	36

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. LENZ, VTVT, UNCY, VANI, and AARD

How does MIRA Pharmaceuticals compare to LENZ Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to vTv Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Vivani Medical?

Summary

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. LENZ, VTVT, UNCY, VANI, and AARD

How does MIRA Pharmaceuticals compare to LENZ Therapeutics?

Which has preferable earnings and valuation, MIRA or LENZ?

Does the media refer more to MIRA or LENZ?

Is MIRA or LENZ more profitable?

Do insiders & institutionals hold more shares of MIRA or LENZ?

Which has more volatility & risk, MIRA or LENZ?

Do analysts recommend MIRA or LENZ?

Summary

How does MIRA Pharmaceuticals compare to vTv Therapeutics?

Does the media prefer VTVT or MIRA?

Is VTVT or MIRA more profitable?

Do analysts rate VTVT or MIRA?

Do institutionals and insiders hold more shares of VTVT or MIRA?

Which has better valuation & earnings, VTVT or MIRA?

Which has more volatility & risk, VTVT or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Does the media refer more to MIRA or UNCY?

Do institutionals & insiders have more ownership in MIRA or UNCY?

Is MIRA or UNCY more profitable?

Which has stronger earnings and valuation, MIRA or UNCY?

Do analysts rate MIRA or UNCY?

Which has more risk and volatility, MIRA or UNCY?

Summary

How does MIRA Pharmaceuticals compare to Vivani Medical?

Which has more volatility & risk, MIRA or VANI?

Does the media refer more to MIRA or VANI?

Is MIRA or VANI more profitable?

Do insiders and institutionals have more ownership in MIRA or VANI?

Do analysts rate MIRA or VANI?

Which has higher earnings & valuation, MIRA or VANI?

Summary

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Is AARD or MIRA more profitable?

Do analysts prefer AARD or MIRA?

Which has better valuation & earnings, AARD or MIRA?

Do institutionals and insiders hold more shares of AARD or MIRA?

Which has more risk and volatility, AARD or MIRA?

Does the media prefer AARD or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools